3177 results for «386»
3177 results
Ultrasound renal denervation is now guideline-recommended: how do I get started?
20 May 2025 – From EuroPCR 2025
Ultrasound renal denervation (uRDN) is now guideline-recommended—are you ready to bring it into practice? This EuroPCR 2025 session offers everything you need to get started: review key results from Sham-controlled and off-medication trials confirming the efficacy and safety of RDN; understand why both the ESC and...
Valve choice - Shaping index procedures and lifetime patient management
22 May 2025 – From EuroPCR 2025
This session addresses recent advancements and ongoing challenges in transcatheter aortic valve implantation (TAVI), with a particular focus on valve selection during index procedures. Presentations include data from the Accurate IDE trial, highlighting the prognostic implications of valve underexpansion. A clinical case involving an 80-year-old patient with severe...
Complex PCI in calcific coronary artery disease - LIVE Case
20 May 2025 – From EuroPCR 2025
A 76-year-old male patient presented with a significant history of coronary artery disease: CABG with LIMA/LAD and RIMA/OM (1996), RCA PCI with BVS (2016), OM PCI (2017), RIMA occlusion and OM retenosis treated with DCB (2022) with preserved LV. He was admitted for pre-operative evaluation prior...
Why should laser atherectomy be part of your complex PCI algorithm?
21 May 2025 – From EuroPCR 2025
Watch this EuroPCR 2025 session to see how ELCA can make the difference in two challenging cases: a severely calcified, undilatable lesion, and an uncrossable one. Learn how pre- and peri-procedural imaging (CT, IVUS, OCT) supports tailored decision-making, and how ELCA enables safe and effective lesion...
How to manage coronary artery disease in TAVI candidates?
20 May 2025 – From EuroPCR 2025
Understand the comprehensive management of coronary artery disease (CAD) in patients undergoing transcatheter aortic valve implantation (TAVI). This session reviews evidence-based evaluation, decision-making, and treatment strategies for significant coronary lesions, including severe left main and multivessel disease, illustrated through detailed case studies.
How a new generation of coronary sinus reducer can significantly expand treatment options for patients with coronary microvascular dysfunction
21 May 2025 – From EuroPCR 2025
Discover the latest on managing coronary microvascular dysfunction (CMD) with insights from EuroPCR 2025. This session explores how physiology testing helps identify CMD endotypes in the cathlab and highlights the limitations of ETT for patients experiencing angina or dyspnea at rest. Learn about the A-FLUX coronary...
Role of imaging in ACS: from non-invasive to invasive investigations
20 May 2025 – From EuroPCR 2025
Explore the critical role of imaging in acute coronary syndrome (ACS) from non-invasive coronary CT angiography to invasive intracoronary imaging modalities. This session covers detection of culprit lesions, diagnostic strategies, and PCI optimization through real-world case examples.
Mitral hotline: new devices
20 May 2025 – From EuroPCR 2025
Stay updated on emerging devices in mitral valve repair and replacement with this session covering novel technologies including transcatheter edge-to-edge repair (TEER), posterior leaflet restoration, transfemoral mitral annuloplasty, and a first-in-human transseptal TMVR system. Clinical trial data and early feasibility experiences provide valuable insights into advancing...
Mitral and tricuspid hotline: long-term outcomes
20 May 2025 – From EuroPCR 2025
Review long-term outcomes of transcatheter edge-to-edge repair (TEER) for mitral and tricuspid valve disease in this session. Highlights include pivotal trial results, mortality risk prediction tools, management of procedural failures, and real-world data, providing comprehensive insights into patient prognosis and therapeutic impact.
Imaging skills for successful TAVI procedure
21 May 2025 – From EuroPCR 2025
Enhance your imaging skills essential for successful TAVI procedures. This session covers complex scenarios such as left circumflex coronary artery anomalies, valve infolding risks with new platforms, bioprosthesis dysfunctions, procedural adaptations when faced with challenges, and zero-contrast TAVI techniques.
Advancing the standard of care in PCI with Bioadaptor: from simple to complex
21 May 2025 – From EuroPCR 2025
This session provides an in-depth overview of Bioadapter technology and its potential to overcome the limitations of current drug-eluting stents (DES) in percutaneous coronary intervention (PCI). Speakers present data from recent trials, including the Bioadapter RCT and the Infinity Sweetheart study, demonstrating a reduction in target lesion...
Management of mitral regurgitation patients undergoing TMVI screening
13 Jan 2022
This study's results emphasise the strengths and limitations of transcatheter mitral valve implantation (TMVI) as a novel and promising therapy providing predictable elimination of MR in most patients, by S. Ludwig et al.
Five-year outcomes of the randomised trial of fractional flow reserve guided PCI compared to coronary artery bypass grafting: FAME 3
02 Apr 2025
Kalaivani Mahadevan provides her take on the five-year outcomes of the FAME 3 trial presented by William F. Fearon at ACC.25 in Chicago.
Author
Everolimus-eluting stents or bypass surgery for mutivessel coronary artery disease: 10-year outcomes of multicenter randomized controlled BEST trial
20 Sep 2022
Nicola Ryan provides her take on the BEST trial which was presented by Jung-Min Ahn at TCT 2022.
It is a randomised, multicentre, non-inferiority trial comparing PCI with second-generation everolimus-eluting stents and CABG in patients with non-left main multivessel coronary artery disease. At two-year follow-up PCI was shown...
Author
Fractional flow reserve-guided complete or culprit-only PCI in patients with ST-elevation myocardial Infarction - FULL REVASC
08 Apr 2024
Nicola Ryan provides her take on the FULL REVASC trial which was presented at ACC.24 in Atlanta and published Simultaneously in NEJM.
The FULL REVASC trial is a multicentre registry-based randomised control trial comparing FFR-guided complete revascularisation of non-culprit lesions versus culprit lesion PCI alone in patients presenting...
Author
A review of the 2024 ESC Guidelines on elevated blood pressure and hypertension
13 Nov 2024
Lucas Lauder and Felix Mahfoud provide a summary of the ESC Guidelines on elevated blood pressure and hypertension presented by John William McEvoy and Rhian Touyz at ESC Congress 2024 in London.
Author
Author
OPTION-STEMI: Immediate versus staged complete revascularisation during index admission in patients with STEMI and multivessel disease
02 Sep 2025
Mirvat Alasnag provides her take on OPTION-STEMI, presented by Youngkeun Ahn at ESC Congress 2025 in Madrid.
Author
